It has been found that MDS patients with both SF3B1 mutations and del(5q) are more similar to isolated del(5q) MDS in terms of immunophenotypic characteristics in the red and ancestral lineages and may benefit more from lenalidomide than Luspatercept in first-line therapy (78). This evidence concerns the gene SF3B1 and myelodysplastic syndrome.